SIGA Files Application Supporting Emergency Use Approval for ST-246 Read more about SIGA Files Application Supporting Emergency Use Approval for ST-246 SIGA Technologies, Inc. Retains KCSA Strategic Communications as Investor Relations Counsel Read more about SIGA Technologies, Inc. Retains KCSA Strategic Communications as Investor Relations Counsel SIGA to Present at Susquehanna's SIGnificant Options in Healthcare Conference Read more about SIGA to Present at Susquehanna's SIGnificant Options in Healthcare Conference SIGA Announces Successful Completion Of Its Smallpox Drug Candidate’s Initial Human Safety Trial. Read more about SIGA Announces Successful Completion Of Its Smallpox Drug Candidate’s Initial Human Safety Trial. SIGA Announces $4.8 Million Grant For SIGA-246, It’s Smallpox Drug Candidate. Read more about SIGA Announces $4.8 Million Grant For SIGA-246, It’s Smallpox Drug Candidate. SIGA Announces $6.0 Million Grant To Support Its Lassa Fever Antiviral Program. Read more about SIGA Announces $6.0 Million Grant To Support Its Lassa Fever Antiviral Program. SIGA Receives $16.5 Million From The NIH To Advance Development Of Its Smallpox Drug Candidate, SIGA-246 Read more about SIGA Receives $16.5 Million From The NIH To Advance Development Of Its Smallpox Drug Candidate, SIGA-246 SIGA Announces Smallpox Treatment Breakthrough - SIGA Drug Completely Prevents Smallpox Disease In Preliminary Primate Trial Read more about SIGA Announces Smallpox Treatment Breakthrough - SIGA Drug Completely Prevents Smallpox Disease In Preliminary Primate Trial SIGA Announces $9.0 Million Private Placement Read more about SIGA Announces $9.0 Million Private Placement SIGA Passes Another Milestone With Smallpox Drug SIGA-246 Read more about SIGA Passes Another Milestone With Smallpox Drug SIGA-246 Pagination First page « First Previous page ‹ Previous … Page 24 Page 25 Page 26 Page 27 Page 28 Current page 29 Page 30 Page 31 Page 32 Next page Next › Last page Last » Subscribe to
SIGA Files Application Supporting Emergency Use Approval for ST-246 Read more about SIGA Files Application Supporting Emergency Use Approval for ST-246
SIGA Technologies, Inc. Retains KCSA Strategic Communications as Investor Relations Counsel Read more about SIGA Technologies, Inc. Retains KCSA Strategic Communications as Investor Relations Counsel
SIGA to Present at Susquehanna's SIGnificant Options in Healthcare Conference Read more about SIGA to Present at Susquehanna's SIGnificant Options in Healthcare Conference
SIGA Announces Successful Completion Of Its Smallpox Drug Candidate’s Initial Human Safety Trial. Read more about SIGA Announces Successful Completion Of Its Smallpox Drug Candidate’s Initial Human Safety Trial.
SIGA Announces $4.8 Million Grant For SIGA-246, It’s Smallpox Drug Candidate. Read more about SIGA Announces $4.8 Million Grant For SIGA-246, It’s Smallpox Drug Candidate.
SIGA Announces $6.0 Million Grant To Support Its Lassa Fever Antiviral Program. Read more about SIGA Announces $6.0 Million Grant To Support Its Lassa Fever Antiviral Program.
SIGA Receives $16.5 Million From The NIH To Advance Development Of Its Smallpox Drug Candidate, SIGA-246 Read more about SIGA Receives $16.5 Million From The NIH To Advance Development Of Its Smallpox Drug Candidate, SIGA-246
SIGA Announces Smallpox Treatment Breakthrough - SIGA Drug Completely Prevents Smallpox Disease In Preliminary Primate Trial Read more about SIGA Announces Smallpox Treatment Breakthrough - SIGA Drug Completely Prevents Smallpox Disease In Preliminary Primate Trial
SIGA Announces $9.0 Million Private Placement Read more about SIGA Announces $9.0 Million Private Placement
SIGA Passes Another Milestone With Smallpox Drug SIGA-246 Read more about SIGA Passes Another Milestone With Smallpox Drug SIGA-246